Results of a ZeNix phase III clinical trial has found that the BPal treatment regimen remains effective against highly drug-resistant strains of tuberculosis with a reduced dosage
BPaL: What it is, and why it’s important?
Developed by a non-profit organization, TB Alliance, Pretomanid is the newest anti-TB drug, prescribed as part of the BPaL regimen, which includes two other drugs – Bedaquiline and Linezolid. Medical practitioners are hoping that this new drug in the BPaL combination will drastically cut short the treatment duration by half (and more), and reduce the amount of medication an MDR-TB patient must take during treatment.
#Science&tech
Course Purchase Query 